Abelacimab Demonstrates Significant Reduction in Bleeding vs Rivaroxaban in Patients With Atrial Fibrillation

The AZALEA-TIMI 71 randomized trial evaluated the safety and tolerability of 2 blinded doses of the novel factor XI inhibitor abelacimab compared with open-label rivaroxaban.

Related Keywords

Massachusetts ,United States ,Philadelphia ,Pennsylvania ,Boston ,American , ,Cardiovascular Division At Brigham ,American Heart Association ,Harvard Medical School ,Data Monitoring Committee ,Cardiovascular Division ,Scientific Sessions ,Anthos Therapeutics ,